The design, characterization and (pre)clinical testing of targeted nanomedicine formulations is the core activity. Clinical translation of academic results is a vital element of Prof. Storm’s ambition. He is on the Board of the CLINAM (European Foundation for Clinical Nanomedicine) organization in Basel, Vice-President of the PRC (Phospholipid Research Center) in Heidelberg, Chairman of the Scientific Advisory Board of the Utrecht Centre for Affordable Biotherapeutics (UCAB), Co-Founder of the spin-off companies Eden Ophthalmic in Singapore and Ayuvant B.V. in Utrecht. Scientific Advisor at Liposoma B.V. in Amsterdam.